Tokai Pharmaceuticals Obtains $23,000,000 Series D Financing Round

  • Feed Type
  • Date
  • Company Name
    Tokai Pharmaceuticals
  • Mailing Address
    One Broadway 11th floor Cambridge , MA 02142
  • Company Description
    The company develops biopharmaceutical products that focus on endocrine treatment.
  • Website
  • Transaction Type
    Venture Equity
  • Transaction Amount
  • Transaction Round
    Series D
  • Proceeds Purposes
    The new money will go toward Tokai’s lone drug in development, galeterone (TOK-001), as it advances into the second of three phases of trials normally required for FDA approval.
  • M&A Terms
  • Venture Investor
    Novartis Venture Fund
  • Venture Investor
    Apple Tree Partners
  • Venture Investor

Trending on Xconomy